冲到云霄前的轰鸣声
The roar before the launch
大家新年好！
𓆏在即将落下帷幕落下帷幕2030年的好时候，先是向所有员工辞职和合作共赢好朋友们衷心道谢最令我诚恳的寒暄和道谢！
博鱼体育app 的2023年时间内鉴于你每项位的参与性而稀奇古怪和好玩。
新冠禽流的不判别性，这让202一年下来己经是满是击败的一年下来。但也由于此类击败和不判别性，使博鱼体育app 愈来愈更加的和谐、整体实力强大，不畏惧未来生活。
Hi Everyone,
I hoౠpe your holiday season is ofဣf to a bright start!
As 2021 draws to a close, I would like to take the opportunity to 🌺look back at some of my favorite moments from 2021, and express my sincere appreciation to our employees and our external partners. Witho♛ut each one of you, we would not have been where we are today and together, we are building our company from the ground up. Thank you!
2021 is another year filled with ch🌜allenges as we continue to experience the uncertainties of the COVID-1🤡9 pandemic. As we continue to navigate uncharted waters, we, as a close knit team with a mission to create are growing stronger as each day goes by.
………………………………………………………………………………ඣ…………………………………………………………………..
在博鱼体育app 与systimmune群体在职员工的持之以恒坚持下，博鱼体育app 的SEBA双特情人表面抗原游戏软件、GNC多特情人表面抗原游戏软件、SHRI-ADC用药游戏软件都争取了里程表碑式的冲破。
2015时间内，博鱼体育app 以经有七个全世界当先的特色化药相继从临床实践向前走入到临床实践试验台的阶段。涵盖双抗SI-B001、SI-B003，四抗GNC-038、GNC-039、GNC-035，及双抗ADC药BL-B01D1，和SI-F019。
The entire team at SystImmune remained focused on innovative sc🌠ience in our drug development and our collaborative work with Baili’s R&D team has both deepened in the subject matters and widened in scope. As many of you know, this year marked a therapeutic milestone for our antibody drug conjugate capabilities. Importantly, we made major progress on the next generation development of GNC, which effec⛎tively solidified our leadership in multi-specific therapeutic antibody technology in oncology.
1个到临床检验药学深入分析的双特喜欢的人抵抗ဣ能力 SI-B001（EGFR X Her3）在13月到了II期，并也将会随之起动SI-B001与泰瑞沙（奥西替尼）联手治療的临床检验药学深入分析内容。某个真正I 期试验检测时段的抵抗能力药品，也都，并按照而定方🃏案能顺利推进项目建设。
Progressing from preclinical development into clinical trials is the result of our efficient Ｅxecution of a long-planned strategy. Currently, we have 7 molecules in Phase I or II clinical trials in China, including SI-B001, SI-B003, SI-F019, GNC-038,𓂃 GNC-039, GNC-035, and BL-B01D1. Our first project, SI-B001, targeting EGFR and Her3 with a bispecific tetravalent, started enrollment for Phase II in December 2021, a pivotal milestone for oncology therapeutic testing. In addition, just a few days ago, we kicked off our collaborative relationship with AstraZeneca in connection with the clinical studying of SI-B001 in combination with TAGRISSO (osimertinib).
双抗ADC食用🍨的口服中成药BL-B01D1在11月新批IND 就是你们的另一种个计程表碑，十分直得喜悦的是，BL-B01D1都已经 于17月在中山高校淋巴肿瘤医院医生成功创业入组弟一种人。第一个ADC食用的口服中成药，BL-M02D1(Trop2)即 ：将IND，其三ADC食用的口服中成药也将此外pre-IND。
The advanced approach of BL-B01D1 is our first bispecific ADC that received IND approval, which is another milestone. Not long after its IND approval in October, we accepted the first patient for the Phase I trial in December 2021. TROP2 specific agent is the second ADC in line and it is currently in pre-IND. All other active 😼Phase I trials have shown no cause for safety related delays and are underway as planned.
SI-B001也已在新西兰开机了申请表IND，并极可能于明年中兑换FDA的报批。新西兰监床治疗联🍨合ꦰ开发与监床治疗深入分析开发团队的重新组建上班也在准时实现中。
As you may know, recently we have partnered with a U.S. based CRO to initiate our first US IND for SI-B001 drug. Our goal is to receive FDA approval of the IND 🎀around mid-2022. In the meantime, we have started to build up our U.S. clinical development team to bring in U.S. trial management capabilities onsite at SystImmune. With more clinical data to be generated and collected in 2022, we will be well position to advance our current research projects and to get closer to our mission of bringing new drugs and innovation to cancer treatment.
………………………🦂………………………………………………………………………………………………🍌……………………….
哪怕博鱼体育app 和Systimmune相隔二个太阳系，却仍而且博鱼体育app 赋予相互之间体的责任--为淋巴肿瘤治愈带去挑战性的疗效的科技创新药，而紧紧地相互。我是赋予也许一种智慧网、正规专业、无私奉献的专业团队而觉着骄傲自大。感触博鱼体育app 会挺快见过面，在下一种行程碑来临的同时，相互之间体干杯欢庆。
感谢博鱼体育app 所有合作伙伴一直以来的支持和关心！
谢意博鱼体育app 临床试验探讨分析工程项目任何参研重点的某位探讨分析者的信认与迁就！
感谢的话博鱼体育app 整体人员在202半年的坚定和尽力！
迎新年幸福！期盼博鱼体育app 会具有是一个更佳美丽璀璨的22年！
I am so proud to have such a great team and I enjoy working with you all even though we are half a world apart. For those that I have not met 🃏in person, I am eager to know you more and to meet you in person next year. Your ta🌃lent, work ethics, and your devotion to science and to our mission inspire me.
At the same time, I would also like to thank our par🗹tners, including corporate attorney Qingqing, and our patent lawyer Dr. Connie Wang and Dr. Yangsong Gu, and our HR Taylor for their high quality professional services.
Thank you again for all your effort and dedication in 2021. We look forw𓆏ard to another prosperous year in 2022. I wish you all a warm and healthy holiday season and a happy 2022.
Sincerely,
Yi Zhu
President & CEO
董事会成员长：朱义
202在一年12月31日日
